ALTAVILLA, AMELIA
 Distribuzione geografica
Continente #
NA - Nord America 258
AS - Asia 182
EU - Europa 109
AF - Africa 7
SA - Sud America 1
Totale 557
Nazione #
US - Stati Uniti d'America 257
SG - Singapore 110
CN - Cina 65
IT - Italia 30
DE - Germania 23
FI - Finlandia 18
SE - Svezia 17
IE - Irlanda 7
CI - Costa d'Avorio 5
FR - Francia 4
GB - Regno Unito 3
ID - Indonesia 3
IN - India 3
BE - Belgio 2
BG - Bulgaria 2
CH - Svizzera 2
TG - Togo 2
AT - Austria 1
BR - Brasile 1
CA - Canada 1
JO - Giordania 1
Totale 557
Città #
Santa Clara 110
Singapore 105
Boardman 44
Chandler 27
Helsinki 18
Bologna 11
Ashburn 10
Falkenstein 9
Munich 8
Dublin 7
Shenzhen 6
Abidjan 5
Shanghai 5
New York 4
Princeton 4
Guangzhou 3
Jakarta 3
Milan 3
Wuhan 3
Ann Arbor 2
Bari 2
Berlin 2
Bern 2
Brussels 2
Des Moines 2
Dongguan 2
Fort Worth 2
Genoa 2
Harbin 2
Lomé 2
Rezzato 2
Shijiazhuang 2
Sofia 2
Southend 2
Turin 2
Amman 1
Baoding 1
Beijing 1
Bergamo 1
Bühl 1
Cambridge 1
Campogalliano 1
Cesena 1
Changsha 1
Chaozhou 1
Fairfield 1
Fuzhou 1
Gaomi 1
Jincheng 1
Kaifeng 1
Linfen 1
London 1
Monza 1
Nanjing 1
Ponte San Pietro 1
Qingdao 1
Redmond 1
San Diego 1
Seattle 1
Toronto 1
Votorantim 1
Wenzhou 1
Xiamen 1
Zhengzhou 1
Totale 446
Nome #
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 79
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 77
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 28
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 25
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents 19
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 19
CAR-T cell therapy: A potential new strategy against prostate cancer 17
PATIENT'S ATTITUDES TOWARDS TREATMENT IN ADVANCED CANCER: HOW THESE ARE IDENTIFIED FROM THEIR PHYSICIAN? 17
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 16
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 16
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses 16
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 16
Visceral disease in castration-resistant prostate cancer 16
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate 16
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone 15
Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA) 14
ERLOTINIB RELATED TOXICITY IN ELDERLY PATIENTS AFFECTED BY NON-SMALL CELL LUNG CANCER (NSCLC) 13
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 13
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 12
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation 11
Dynamic Contrast-enhanced Magnetic Resonance Imaging in the Early Evaluation of Anti-angiogenic Therapy in Metastatic Renal Cell Carcinoma 10
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 10
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 9
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 9
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 9
KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 9
Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma 9
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 8
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 8
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies 8
Clinical and pathological features of primary neuroectodermal tumor/ewing sarcoma of the kidney 8
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone 7
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 6
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules 6
BENEFIT OF POST-DOCETAXEL TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH POOR PERFORMANCE STATUS 5
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 5
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 4
Clinical and pathological features of primary renal synovial sarcoma: Analysis of 64 cases from 11 years of medical literature 4
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: A personal view 4
RELATIONSHIP BETWEEN ENZALUTAMIDE ACTIVITY AND PREVIOUS ANTIANDROGEN WITHDRAWAL SYNDROME (AWS) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 4
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 4
Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC) 4
Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert 4
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 4
null 2
Totale 615
Categoria #
all - tutte 2.499
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.499


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202239 0 0 0 0 0 0 6 1 1 10 12 9
2022/202362 4 10 2 10 7 9 0 1 11 0 3 5
2023/202440 2 3 1 0 1 6 0 15 5 1 2 4
2024/2025474 55 84 41 46 175 54 19 0 0 0 0 0
Totale 615